Current and emerging medical therapies for glaucoma

Area of Science:

• Ophthalmology
• Neuroscience

Background:

• Glaucoma is a leading cause of irreversible blindness, characterized by optic nerve damage and retinal ganglion cell loss.
• Elevated intraocular pressure (IOP) is a primary risk factor, though glaucoma is now defined as an IOP-sensitive optic neuropathy.

Purpose of the Study:

• To review recent advancements in understanding glaucoma pathophysiology and treatment.
• To highlight the significance of diurnal IOP variation in disease progression.
• To explore new therapeutic opportunities based on improved mechanistic insights.

Main Methods:

• Review of current literature on glaucoma.
• Analysis of recent findings in pathophysiological and genetic mechanisms.
• Evaluation of new therapeutic strategies and medications.

Main Results:

• Development of safer, better-tolerated topical medications for IOP control, reducing surgical necessity.
• Identification of diurnal IOP variation as a critical risk factor for glaucomatous optic neuropathy (GON) progression and visual field loss.
• Elucidation of underlying pathophysiological, genetic, and cellular mechanisms of elevated IOP and GON.

Conclusions:

• Improved understanding of glaucoma's complex pathways enhances opportunities for novel therapeutic modalities.
• Ongoing research into IOP regulation and neuroprotection is crucial for managing this vision-threatening condition.
• Personalized treatment strategies considering diurnal IOP fluctuations may improve patient outcomes.